Sentence examples for patient conditioning from inspiring English sources

This may then be followed by the transfer of autologous haematopoietic cells (auto-HCT; cells harvested from the recipient before patient conditioning (Fig. 1)) or allogeneic haematopoietic cells (allo-HCT; cells harvested from donors rather than the recipient (Fig. 2)) to restore the host immune system.

It has become increasingly apparent that anti-tumor efficacy using adoptively transferred T cells is linked to their duration of in vivo persistence and can only be achieved when combined with some form of pre-infusion patient conditioning regimen.

A single tumor-reactive antigen-specific CTL clone expanded to 1010 cells/m2 is used for both a first infusion given to patients without conditioning, and then, for a second infusion, following patient conditioning.

Patient conditioning was performed using cyclophosphamide and rabbit anti-thymocyte globulin (rATG) (Thymoglobuline; Genzyme, Cambridge, MA).

A more accurate HLA class I and II matching together with improved graft preparations, patient conditioning, and targeted prophylaxis have been essential to decrease the incidence of GvHD, especially in the context of malignant diseases.

Here, LV delivery of second generation CARs (with CD3ζ and 4-1BB domains) was combined with patient conditioning with combinations of cyclophosphamide, bendamustine, penotatsin and etoposide in patients with CLL and acute lymphoblastic leukaemia (ALL) (Kalos et al, 2011; Porter et al, 2011; Grupp et al, 2013).

In some cases, this fear restricts patients conditioning their social relations.

Anti-Aspergillus prophylaxis should probably be used in high-risk critically ill neutropenic patients (myeloablative conditioning regimens, older patients, transplant in patients with active disease, umbilical/placental cord blood transplant) (Grade 2 + , weak agreement).

Further, analysis of pharmacokinetic data of the patient's conditioning regimens indicated that they were unlikely to impact cell viability, which is consistent with the patient's CD4 T cell count, which remained >300 cells/mm as VL control was regained.

Both patients received conditioning with Fludarabine/Cytoxan/Campath 1H (alemtuzumab, anti-CD52 antibody) and T-cell-depleted donor cells with Campath-1H.

Due to the high variability of treated patients, different conditioning regimens were used (Table  2).